This is a routine regulatory expansion — no new clinical data or change in trial timeline. Monitor for actual trial initiation in Q4 2026 and any early safety/efficacy readouts, which are the true catalysts. The stock's 92% analyst bullish consensus already prices in pipeline progress.
Price Chart
Executive Summary
CAMP4 received MHRA authorization to include UK sites in its global Phase 1/2 trial of CMP-002 for SYNGAP1-related disorder, building on prior clearances in Australia and Argentina. The company remains on track to initiate the study in Q4 2026, but this is a procedural regulatory step with no new clinical data or change in probability of success.
Key Facts
- MHRA authorized UK sites for CAMP4's Phase 1/2 trial of CMP-002 in SYNGAP1-related disorder
- Prior clearances received from Australia's TGA/HREC and Argentina's ANMAT in July 2026
- Company on track to initiate the clinical trial in Q4 2026
- Regulatory filings in the European Union remain under review
- SYNGAP1 affects over 10,000 individuals in the US with no approved disease-modifying therapies
Financial Impact
No financial data disclosed; regulatory milestone with no revenue or funding impact
Risk Factors
- Clinical trial enrollment delays or safety issues
- Need for substantial additional financing to complete development
- Competition from other SYNGAP1 programs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3359400 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | Press Release | $4.34 $4.03 | ▼ −7.14% | ▼ −6.64% | $3.73 (−13.95%) |
Sep 2, 2026 29d ago | Insider Cluster | $4.49 $4.25 | ▼ −5.35% | ▼ −4.20% | $3.73 (−16.83%) |
Aug 21, 2026 6w ago | Insider Cluster | $4.48 $4.15 | ▲ +7.37% | ▲ +7.84% | $3.73 (+16.64%) |
Aug 13, 2026 7w ago | EFFECT | $4.50 $4.45 | ▼ −1.11% | ▲ +0.85% | $3.73 (−17.01%) |
Aug 5, 2026 8w ago | Insider Cluster | $4.50 $4.50 | · 0.00% | ▼ −1.21% | $3.73 (−17.01%) |
Aug 5, 2026 8w ago | Insider Cluster | $4.50 $4.50 | · 0.00% | ▼ −1.21% | $3.73 (−17.01%) |
Jul 27, 2026 9w ago | 8-K | $3.42 $3.45 | ▲ +0.88% | ▼ −0.20% | $3.73 (+9.20%) |
Jun 19, 2026 14w ago | Press Release | $4.20 $4.20 | · 0.00% | ▲ +2.07% | $3.73 (−11.08%) |
Jun 12, 2026 15w ago | 8-K | $3.96 $4.20 | ▲ +6.06% | ▲ +7.44% | $3.73 (−5.69%) |
Jun 11, 2026 16w ago | Institutional Cluster | $4.22 $4.14 | ▼ −1.90% | ▼ −2.33% | $3.73 (−11.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access